Literature DB >> 10707874

Basement membrane peptides as markers of liver disease in chronic hepatitis C.

K M Walsh1, A Fletcher, R N MacSween, A J Morris.   

Abstract

BACKGROUND/AIM: Chronic hepatitis C is characterised by slow progression to liver fibrosis. In liver fibrosis, basement membrane components are increasingly deposited around the vessels and in the portal tracts. Serum assays can measure the two major components of the basement membrane, type IV collagen and laminin. The aim of this study was to determine whether serum levels of type IV collagen and laminin are related to severity of liver injury in chronic hepatitis C.
METHODS: Thirty-seven patients with chronic hepatitis C (CHC) and five healthy controls were studied. Serum type IV collagen was measured by a one-step sandwich EIA kit (Fuji, Japan) and serum laminin was measured by RIA (CIS, UK). Liver biopsies in patients with CHC were scored using a previously described grading and staging system. Liver biopsy scores were compared to serum levels of laminin, type IV collagen and alanine aminotransferase (ALT). Receiver operating characteristic (ROC) analysis was used to compare the ability of the assays to detect advanced liver injury.
RESULTS: The median serum concentration of type IV collagen was 127.1 ng/ml (range 17.7 to 317.4) in CHC patients compared to a median of 61.3 ng/ml (range 11.5 to 102.3) in controls, p=0.006. The median serum concentration of laminin was 1.12 U/ml (range 0.74 to 2.46) in CHC compared to a median of 0.87 U/ml (range 0.83 to 1.06) in controls, p=0.07. Both serum type IV collagen and laminin were significantly correlated with the fibrotic stage and also with the necroinflammatory injury scores- histological activity index, portal inflammation and periportal hepatitis. Serum ALT was significantly correlated with portal inflammation. Using ROC analysis, the area under the curve for type IV collagen and laminin was 0.83 (p=0.001) and 0.82 (p=0.0017), respectively, while the area under the curve for ALT was 0.54 (p=0.1).
CONCLUSIONS: Serum assays of basement membrane peptides are accurate non-invasive markers of liver fibrosis and liver inflammation in chronic hepatitis C. These markers are superior to serum ALT in reflecting liver injury and they have high specificity and sensitivity in detecting advanced liver disease in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10707874     DOI: 10.1016/s0168-8278(00)80079-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  Non-invasive diagnosis of liver fibrosis.

Authors:  Hiroyasu Morikawa; Norifumi Kawada
Journal:  Clin J Gastroenterol       Date:  2011-07-31

Review 2.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

3.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

Review 4.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis.

Authors:  Min Zheng; Wei-Min Cai; Hong-Lei Weng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.

Authors:  F Serejo; A Costa; A G Oliveira; F Ramalho; A Batista; M C De Moura
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

Review 7.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

8.  Serum laminin and collagen IV in inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; P Dimoulios; E Vardas; M Roussomoustakaki; A N Maniatis; E A Kouroumalis
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

9.  Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.

Authors:  Giada Sebastiani
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

10.  Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis.

Authors:  Sanne S Veidal; Morten A Karsdal; Arkadiusz Nawrocki; Martin R Larsen; Yueqin Dai; Qinlong Zheng; Per Hägglund; Ben Vainer; Helene Skjøt-Arkil; Diana J Leeming
Journal:  Fibrogenesis Tissue Repair       Date:  2011-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.